Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now

You can switch off notifications anytime using browser settings.
Stock Analysis, IPO, Mutual Funds, Bonds & More

Sun, CSIR-IICT Ink Global Licensing Pact for Patents

'This collaboration with CSIRIICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline.'

, ET Bureau|
Aug 15, 2019, 07.23 AM IST
MUMBAI: In one of the rare partnerships between the industry and academic institutions, Sun Pharma, India’s largest drug maker, said that it has entered into a global licensing agreement with Hyderabad based CSIR Indian Institute of Chemical Technology for patents related to certain therapy areas with multiple indications.

Sun has made an upfront payment of Rs 240 crore to the institute and as per the terms of the agreement, CSIR, Hyderabad will also receive royalties on net sales from the commercialisation of these products.

“This collaboration with CSIRIICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline. CSIR-IICT is well-known for its high quality research and we are proud to be associated with them. We are making earnest efforts to bring innovations from Indian research institutes to the market to address the unmet needs of patients globally,” said Dilip Shanghvi, managing director, Sun Pharma.

Sun pharma said the agreement will facilitate addition of pre-clinical candidates to Sun Pharma’s global specialty pipeline. For the quarter ending June 2019, Sun Pharma reduced its R&D spend. Its R&D investment for Q12020 was Rs 422 crores compared to Rs 500 crores for Q1FY19. Shares of Sun Pharma closed on Wednesday at Rs 417.05, down 4.7%.

In the last few years Sun Pharma has been ramping up its speciality portfolio where it has taken its new molecules to geographies beyond US.

Its new drug Tildrakizumab has been out licensed in countries like China and the company is preparing to launch it in Japan. Sun in its analyst presentation said these launches reflect its global aspirations for speciality business. The global speciality business for the company contributed $94mn of its total sales.

Also Read

Sun Pharma to make upfront payment worth Rs 2.40 bn to CSIR-IICT Hyderabad for new drug compounds

Scientist Srivari Chandrasekhar named Director of IICT

IICT develops new technology to manufacture hydrazine hydrate

CSIR-IICT develops hydrofluorocarbons manfacture technology to reduce global warming by refrigerators

Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.

Other useful Links

Follow us on

Download et app

Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service